$DORM

Dorman Products Q2 net sales rise to $544.6 million

Dorman Products reported Q2 2026 net sales of $544.6 million, up 0.7% from $541.0 million. Net income rose to $87.8 million and diluted EPS increased 53% to $2.93, aided by IEEPA tariff cost recovery, according to the company. Operating cash flow was $152.6 million; it repurchased $47 million of shares. Updated guidance: net sales growth 3% to 5% and EPS $7.93 to $8.23.

Original reporting
Published Aug 3, 2026, 8:36 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 3, 2026, 9:26 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Dorman Products Q2 net sales rise to $544.6 million — source image
Decision brief

The 30-second read

$DORMBullishMed
01

Why it matters

Traders can update models using the new Q2 datapoints (sales, net income, EPS, gross margin, cash flow) and the revised FY 2026 net sales and EPS ranges, then reassess expectations for tariff-related margin support.

02

Market read

A concrete earnings and guidance update for Dorman, with tariff-recovery as the key driver and an upcoming call that can clarify durability.

03

What to watch

Segment mix (Light Duty vs Heavy Duty vs Specialty Vehicle) and the sustainability of operating cash flow versus working-capital swings could matter more than the headline EPS beat.

Relevance 8/10Novelty 8/10Timing: after-hours Q2 results and guidance update, ahead of Aug 4 investor call

Background

Dorman Products is an auto parts supplier; the article frames Q2 performance around IEEPA tariff cost recovery and provides updated full-year 2026 guidance.

Company-level read

Ticker impact

$DORMBullishMedium confidence
Context

Dorman reported Q2 2026 net sales of $544.6M and raised diluted EPS 53% to $2.93, citing IEEPA tariff cost recovery.

Expected impact

Likely supportive for the stock into the Aug 4 investor call, assuming guidance is viewed as credible versus tariff-related normalization risk.

Evidence & confidence

Reported results include higher net income and EPS, operating cash flow of $152.6M, and explicit updated FY 2026 targets ($7.93 to $8.23). The key swing factor is the extent to which IEEPA tariff cost recovery is repeatable.

Market effects

Tariff-cost recovery dynamics can affect auto-parts margin expectations across suppliers with similar exposure.

Limited direct regional spillover; primarily US small/mid-cap auto-parts sentiment.

IEEPA tariff mechanics are US policy-driven, but can influence global supply-chain cost assumptions for parts makers.

Counterpoint

Tariff cost recovery may be non-recurring; margins and EPS could mean-revert if recoveries fade or timing shifts.

Key entities

  • Dorman Products

    Reported Q2 2026 net sales of $544.6M, net income of $87.8M, and diluted EPS of $2.93, plus updated FY 2026 guidance.

  • IEEPA tariff cost recovery

    Stated contributor to earnings and operating cash flow in the quarter.

  • Aug 4, 2026 investor conference call

    Scheduled at 8:00 a.m. Eastern Time following the earnings release.

Related articles

$DORMMedAI 8/10

Dorman Products (DORM) Q2 2026 Earnings Call Transcript

Dorman Products (DORM) reported Q2 2026 net sales of $544.6 million (+0.7%) and adjusted diluted EPS of $3.08 (+50%), helped by a $1.18 per share IEEPA tariff refund. Adjusted gross margin rose to 46.1%. FY2026 guidance: net sales growth 3% to 5% and adjusted EPS $8.50 to $8.80.

$DORMMed

Dorman Products, Inc. (DORM): Results of Operations and Financial Condition

Dorman Products, Inc. (DORM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Dorman Products, Inc. Reports Second Quarter 2026 Results; Updates 2026 Guidance Highlights (All comparisons are to the prior year period unless otherwise noted) : • Net sales of $544.6 million for the quarter, up 0.7% • Diluted earnings per share (“EPS”) of $2.93, u

$EQIXMedAI 8/10

Equinix Is Doubling Down on AI Data Centers. How to Play EQIX Stock Here

Equinix (EQIX) reported Q2 revenue of $2.63B, up 16% YoY, beating estimates. AFFO was $11.78/share, up 19% YoY. The company raised full-year guidance and unveiled a multi-year growth plan. EQIX stock has surged 34% over the past year and offers a 1.98% dividend yield. Analysts rate it a 'Strong Buy' with an average price target of $1,232.19.

$IBKRMedAI 8/10

Interactive Brokers Earns Interest on $182 Billion of Its Clients' Idle Cash. Will Anthropic's IPO Drain It?

Interactive Brokers (IBKR) reported $182.4B in uninvested client cash, up 27% YoY, earning interest until invested. Anthropic's potential $2T IPO could impact cash levels, but SpaceX's IPO didn't drain IBKR's reserves. IBKR's Q2 net interest income rose 23% to $1.06B, half of total revenues. Client accounts and trading activity grew, mitigating cash outflows. IBKR stock is near $92, trading at 29x next year's earnings.

$ORCLMedAI 8/10

Oracle’s AI Earnings Story Is Improving, but the Cash Flow Test Remains

Oracle (ORCL) reported strong Q4 earnings with 21% revenue growth and raised its profit forecast. Morgan Stanley increased its price target to $210, citing improved GPUaaS margins. However, the company faces cash flow pressure due to high capital expenditures for AI infrastructure, with free cash flow at negative $23.7 billion. Hedge funds remain invested, with Fisher Asset Management increasing its stake.